Selective inhibition of BET bromodomains; Histone recognition and large-scale structural analysis of the human bromodomain family; Targeting bromodomains: epigenetic readers of lysine acetylation; Protein production and purification; The promise and peril of chemical probes; Critical residues for structure and catalysis in short-chain dehydrogenases/reductases; The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs; Bromodomains as therapeutic targets; Large-scale structural analysis of the classical human protein tyrosine phosphatome; Linear motif atlas for phosphorylation-dependent signaling; Small-molecule inhibition of BRDT for male contraception; Copper is required for oncogenic BRAF signalling and tumorigenesis; RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain; The bromodomain interaction module; Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy; PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers; A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases; Crystal structure of the tetrameric Mad1–Mad2 core complex: implications of a ‘safety belt’binding mechanism for the spindle checkpoint; Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?; The (un) targeted cancer kinome
